Le syndrome malin des neuroleptiques

Revue Medicale de la Suisse Romande

Volumn 116, Issue 9, 1996, Pages 713-717

  Bryois, Christian ^a   Bondolfi, Guido ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DANTROLENE; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT;

DIFFERENTIAL DIAGNOSIS; HUMAN; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTOR; SHORT SURVEY; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DIBENZOTHIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; MALE; METHOTRIMEPRAZINE; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 0029797280     PISSN: 00353655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Delay J., Deniker P.: Drug induced extrapyramidal syndromes. In: Handbook of clinical neurology: disease of the basal ganglia. Virka P.J., Bruyn G.W. Eds, vol. 6: 248-266, 1968.
2. Calanca A., Bryois C., Buclin T: Vademecum de thérapeutique psychiatrique. Med. & Hyg., 28-30, 1995.
3. Levenson J.L: Neuroleptic malignant syndrome. Am. J. psychiatr., 142: 1137-1145, 1985.
4. Pope H.G., Keck P.E., Mc Elroy S.I.: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. psychiatr., 143: 1227-1233, 1986.
5. Addonizio G., Susman V., Roth S.D.: Symptoms of neuroleptic malignant syndrome in 82 consecutive in patients. Am. J. psychiatr., 143: 1587-1590, 1986.
6. Adityanjee, Singh S., Singh G. et al.: Spectrum concept of neuroleptic malignant syndrome. Br. J. psychiatry, 153: 107-111, 1988.
7. Gurrera R.J., Chang S.S., Romero J.A.: A comparison of diagnostic criteria for neuroleptic malignant syndrome. J. clin. psychiatry, 53: 56-62, 1992.
8. Gelenberg A.J., Bellinghausen B., Woyciky D. et al.: A prospective survey of neuroleptic malignant syndrome in a short term psychiatric hospital. Am. J. psychiatr., 145: 517-518, 1988.
9. Deng M.Z., Chen G.Q., Phillips M.R.: Neuroleptic malignant syndrome in 12 of 9792 chinese in patients exposed to neuroleptic: a prospective study. Am. J. Psychiatry, 147:1149-1155, 1990.
10. Modestin J., Toffler G., Drescher J.P.: Neuroleptic malignant syndrome: Results of a prospective study. Psychiatry Research, 44: 251-256, 1992.
11. Addonizio G., Susman V.L., Roth S.D.: Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol. psychiatr., 22: 1004-1020, 1987.
12. Weller M., Kornhuber J.: Does clozapine cause neuroleptic malignant syndrome? J. clin. psychiatry, 54: 70-71, 1993.
13. Levinson D.F., Simpson G.M.: Neuroleptic-induced extrapyramidal symptoms with fever. Arch. gen. psychiatry, 43: 839-848, 1986.
14. Mann S.C., Caroff S.N.: Neuroleptic malignant syndrome and lethal catatonia. Am. J. psychiatr., 144: 1369-1370, 1987.
15. Castillo E., Rubin R.T., Holsboer-Trachsler E.: Clinical differentiation between lethal catatonia and neureoleptic malignant syndrome. Am. J. psychiatry, 146: 324-328, 1989.
16. Bryois C.: Le syndrome de stupeur catatonique. J. psychiat. biol. et therap., 34: 29-33, 1989.
17. Bryois C.: Pour une approche psychiatrique pluridimensionnelle au sujet d'un cas de catatonie aiguë. Actualités psychiatriques, 9: 25-30, 1989.